New shuttle session with our in vivo syngeneic tumor models for cost-saving efficacy studies

07 / 16 / 2019

-
Explicyte is providing a series of syngeneic mouse tumor models with either subcutaneous and orthotopic implantation (such as CT26, MCA205, 4T1, MC38, GL261…), which were fully characterized in terms of their responsiveness to immune checkpoint inhibitors (for example PD1/PDL1 axis blockade) and their immune infiltration features.

We are planning a new in vivo shuttle session by mid September, thereby offering an opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic tumor models, over studies where a significant cost part will be supported by ourselves.

As cost-effective studies, only experimental test groups will be at the Sponsor’s expense, while vehicle- and reference-treated groups will be supported by Explicyte.




Figure 1: Subcutaneously-implanted MCA205 sarcoma and 4T1 breast tumor-bearing mouse models are differentially sensitive to PDL1 blockade. Mice were subcutaneously implanted with respective tumor cells and exposed to anti-PDL1 antibody. Tumor growth was monitored overtime via calipering. Tumor volume and survival were then determined. The two tumor models exhibit differential responsiveness levels ; MCA205 being strongly responsive while 4T1 model is only very slightly sensitive.




Figure 2: Differential responses of the subcutaneously-implanted CT26 colon tumor-bearing mouse model to immune checkpoint inhibitors and chemotherapy. A. Mice were challenged with CT26 tumor cells and exposed to either anti-CTLA4, anti-PD1 or anti-PDL1 antibodies, or to 5FU treatment. Contrarily to the strong response to anti-CTLA4 antibody, CT26 tumor is partially responsive to PD1/PDL-1 blockade. A partial response is also observed upon 5FU treatment. B. Mice were challenged with CT26 tumor cells and exposed to anti-PDL1 antibody and a small molecule drug, each alone and in combination. Tumor growth was monitored overtime via calipering. Tumor volume and survival were then determined. Responsiveness of CT26-tumor bearing mice to PDL1 blockade is optimized when combined with the small molecule drug.



Shuttle for efficacy assessment on 6-week experimental session

  • Model / Strain: According to the Sponsor's requirements
  • Readouts: Tumor growth / Body weight / Survival
  • Standard reference: Immune checkpoint inhibitor – to be discussed with the Sponsor
  • Group size: At least 10 mice per group
     
Optional analyses: Satellite studies for immune response profiling and MoA delineation (flow cytometry, gene expression analysis, immunohistochemistry…). Contact us for further information.